Here are the DEF 14A proxy statements from American Well Corporation (AMWL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AMWL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMWL filings page.
American Well Corporation (Amwell) is asking stockholders to vote at its 2026 virtual annual meeting on electing two Class III directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving executive pay on an advisory basis. The proxy also reviews 2025 performance, highlighting a shift to a tech‑enabled care platform and stronger operating discipline. Amwell recorded 2025 total revenue of $249.3 million, including $132.4 million of subscription revenue and $94.3 million of AMG visit revenue, with a 53% gross margin. Net loss narrowed to ($95.0) million from ($212.6) million in 2024, and total visits reached 4.5 million. Year‑end cash and short‑term securities were about $182.3 million. Management reiterates a goal of achieving positive operating cash flow in 2026 and emphasizes its Defense Health Agency SaaS deployment, AI‑enabled programs, and corporate responsibility initiatives. The Board remains majority‑independent and classified, and Amwell is a NYSE “controlled company” through Class B voting shares held by its co‑founders.